A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER
Kongre ve sempozyumlar > Kongre · 2018
Yazarlar: Tuncay GÖKSEL
2018-2018, A randomized phase 3 study of abemaciclib versus erlotinib in previously treated patients with stage IV NSCLC with KRAS mutation: JUNIPER, Kongre, Katılımcı, Amerika Birleşik Devletleri, Colorado